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Abstract
Increasing evidence indicates that RNA interference (RNAi) may be used to provide antiviral
immunity in mammalian cells. Human micro (mi)RNAs can inhibit the replication of a primate virus,
whereas a virally-encoded miRNA from HIV inhibits its own replication. Indirect proof comes from
RNAi suppressors encoded by mammalian viruses. Influenza NS1 and Vaccinia E3L proteins can
inhibit RNAi in plants, insects and worms. HIV-1 Tat protein and Adenovirus VA RNAs act as RNAi
suppressors in mammalian cells. Surprisingly, many RNAi suppressors are also inhibitors of the
interferon (IFN)-induced protein kinase R (PKR) but the potential overlap between the RNAi and
the IFN pathways remains to be determined. The link between RNAi as an immune response and
the IFN pathway may be formed by a cellular protein, TRBP, which has a dual role in HIV replication
and RNAi. TRBP has been isolated as an HIV-1 TAR RNA binding protein that increases HIV
expression and replication by inhibiting PKR and by increasing translation of structured RNAs. A
recent report published in the Journal of Virology shows that the poor replication of HIV in
astrocytes is mainly due to a heightened PKR response that can be overcome by supplying TRBP
exogenously. In two recent papers published in Nature and EMBO Reports, TRBP is now shown
to interact with Dicer and to be required for RNAi mediated by small interfering (si) and micro
(mi)RNAs. The apparent discrepancy between TRBP requirement in RNAi and in HIV replication
opens the hypotheses that RNAi may be beneficial for HIV-1 replication or that HIV-1 may evade
the RNAi restriction by diverting TRBP from Dicer and use it for its own benefit.
RNA interference (RNAi) is a natural antiviral mechanism
in plant and insect cells. It can also be induced by mam-
malian and insect viruses in Caenorhabditis elegans,
although there is no worm-specific virus isolated so far.
An increasing number of observations indicate that RNAi
may also be used by mammalian cells to counteract virus
infection as a natural innate immunity [1-6]. A large
number of mammalian viruses have been downregulated
in vitro and in vivo by RNAi using exogenous small inter-
fering (si)-, short hairpin (sh)- or micro (mi)- RNAs,
showing that mammalian cells have the potential to
mediate RNAi and to inhibit viruses by this mechanism
[7,8]. In addition to cytokine production and the inter-
feron (IFN) response, higher eukaryotes may have devel-
oped the RNAi mechanism as an additional innate
immune response to pathogen infection. Alternatively,
cells may have adapted this ancient mechanism required
for developmental regulation as a response to prevent
invasion by exogenous nucleic acids.
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Retrovirology 2005, 2:65 http://www.retrovirology.com/content/2/1/65Several pieces of evidence support the role of RNAi as an
antiviral immune response in mammalian cells [5]. Viral
miRNAs isolated from cells infected by Epstein-Barr virus
(EBV) and HIV-1 constitute the first evidence of a role of
the RNAi mechanism during viral infection [9,10]. Retro-
viruses provide another example showing that a cellular
miRNA restricts the replication of the primate foamy virus
PFV-1 in human cells [11]. Other indirect support for this
hypothesis is the presence of virus-encoded RNAi suppres-
sors. Influenza virus NS1 and vaccinia E3L proteins, two
inhibitors of the IFN-induced protein kinase R (PKR),
inhibit RNAi pathways in plants and in Drosophila cells
[12]. HIV-1 Tat protein acts as an RNAi suppressor in the
pathway mediated by shRNAs but not siRNAs, suggesting
a specificity of action [10]. Adenovirus VA RNAI and VA
RNAII are cleaved by Dicer and act as RNAi suppressors
[13]. Both Tat protein and VA RNAs inhibit Dicer activity.
A striking feature of RNAi suppressors characterized thus
far from mammalian viruses is that most are also inhibi-
tors of PKR, either by direct binding, by RNA sequestra-
tion or by substrate competition [14]. However, this
feature is not shared by plant and insect silencing suppres-
sors. This characteristic suggests a link or an overlap
between the mechanism of RNAi and the PKR pathway in
mammalian cells. One common feature is that both
mechanisms are triggered by dsRNA, but three recent
papers published in Nature, EMBO Reports and the Jour-
nal of Virology establish another link through a double-
stranded (ds) cellular RNA binding protein, TRBP. TRBP
binds Dicer and is part of the RNA-induced silencing com-
plex (RISC), but it is also a strong inhibitor of PKR respon-
sible for enhancement of HIV-1 replication [15-17].
TRBP was isolated as an HIV-1 trans-activation response
(TAR) RNA binding protein that enhances virus expres-
sion [18,19]. It belongs to the family of dsRNA binding
proteins with two dsRBDs and a KR-helix motif within
dsRBD2 that mediates RNA binding. A third C-terminal
basic domain does not mediate RNA binding [20,21].
TRBP is a strong PKR inhibitor by direct binding through
its dsRBDs and by dsRNA sequestration [22-24]. TRBP
also has a direct activity on translation independent of
PKR but dependent on a structured RNA [25]. All assays
done thus far with HIV show that the protein contributes
positively to the enhancement of HIV-1 expression and
replication (Fig. 1). A recent paper in the Journal of Virol-
ogy further demonstrates this ability. In Ong et al., [17]
published in the October 15 issue (chosen as a spotlight
by the editors), the authors demonstrate that HIV-1 repli-
cates poorly in astrocytes because of a heightened PKR
response, that mediates poor translation of the viral struc-
tural proteins. They demonstrate that HIV replication can
be rescued by expressing low amounts of the PKR inhibi-
tor TRBP. In this context, TRBP prevents PKR activation,
restores the production of viral proteins and consequently
HIV replication. The profound impact of TRBP transfec-
tion in these cells comes from its low endogenous expres-
sion due to a weak activity of TRBP promoter [26]. The
low permissivity to HIV replication in astrocytes can
therefore be ascribed in large part to low TRBP expression.
This recent paper provides an additional mechanistic
explanation for the low HIV replication in astrocytic cells
and demonstrates the key role of TRBP in virus translation
by counteracting the antiviral immunity mediated by
PKR.
At the same time two papers published recently in Nature
and EMBO Reports show that TRBP binds Dicer, that it is
part of RISC, and that it is required for RNAi in human
cells [15,16]. In both papers, the authors isolated ribonu-
cleoprotein complexes containing Dicer, analyzed them
by gel electrophoresis and mass spectrometry. Argonaute2
(Ago2) and TRBP were among the proteins found repro-
ducibly in the complex. The interaction between TRBP
and Dicer was confirmed by immunoprecipitation and in
vitro interaction. Haase et al., show that the interaction is
independent from RNA and that the complex cofraction-
ates with the miRNA miR-17. By using a two-hybrid assay,
they map the interaction to the C-terminal domain in
TRBP, which is devoid of RNA binding activity, providing
further evidence of a direct interaction between the two
TRBP acts in the cell by at least three different mechanismsFigure 1
TRBP acts in the cell by at least three different 
mechanisms: i) it enhances translation by binding to dsR-
NAs; ii) it binds to PKR and inhibits its function;iii) it partici-
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Retrovirology 2005, 2:65 http://www.retrovirology.com/content/2/1/65proteins. Chendrimada et al., show that TRBP forms ribo-
nucleoprotein complexes composed of [siRNA-TRBP-
Dicer-Ago2], indicating that TRBP appears as the bridge
between dsRNA and Dicer for Ago2 recruitment. Using
siRNAs against either TRBP or Dicer and subsequent
immunoprecipitation of Ago2, the authors show a
decrease in both TRBP and Dicer concluding to a loss of
stability of the reciprocal partner. However, this decrease
rather indicates that Ago2 requires both proteins to effec-
tively bind the complex. Using the same siRNAs, they fur-
ther show a decrease in mature miRNA production and a
loss of siRNA function either after TRBP or after Dicer
depletion. They conclude that TRBP recruits Ago2 to RISC
and that it couples the initiation and the execution steps
of RNAi. Haase et al., show that in vitro processing, but not
in vivo steady-state levels of miRNAs, is decreased by TRBP
depletion. SiRNAs against TRBP did not cause destabiliza-
tion of Dicer, but decreased the efficiency of RNAi medi-
ated either by miR17 or by an anti-lamin siRNA,
indicating that TRBP is involved in both processes. The
conclusion of both papers is that TRBP is a partner of
Dicer that is required for siRNA as well as miRNA function
in human cells.
Considering that TRBP is required both for RNAi and for
an efficient HIV replication, it is difficult to understand
how RNAi could function as a cellular antiviral mecha-
nism against HIV. In this regard, two possibilities arise: 1)
Instead of mediating antiviral immunity, RNAi could be
beneficial for the virus and 2) HIV may divert TRBP and
use it for its own benefit to avoid RNAi cleavage.
1) Could HIV replication benefit from the RNAi pathway?
Because RNAi is a mechanism that cleaves RNAs homolo-
gous to defined siRNAs, it should participate to the elimi-
nation of unwanted exogenous RNA to protect the cell.
However, numerous examples show that viruses also co-
opt cellular pathways and use them for their own replica-
Model for the role of TRBP during the early steps of viral infectionFigure 2
Model for the role of TRBP during the early steps of viral infection. A) HIV co-opts the RNAi pathway for its 
own benefit. After the uncoating steps, the viral RNA is released in the cytoplasm. The TRBP-Dicer complex binds to viral 
and cellular RNAs and cleaves small dsRNAs that inhibit PKR. B) HIV diverts TRBP from Dicer to avoid the cleavage of 
its RNA. The viral RNA released in the cytoplasm binds TRBP, which becomes unavailable for interaction with Dicer. The 
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Retrovirology 2005, 2:65 http://www.retrovirology.com/content/2/1/65tion [14]. Therefore, we cannot exclude that the RNAi
pathway can support HIV replication and possibly other
viruses. Indeed, one recent study shows that a liver-spe-
cific miRNA, miR-122, facilitates hepatitis C virus (HCV)
replication, although in this case, the virus and the cell
may have co-evolved with miR-122 [27]. TRBP and Dicer
may be recruited to the TAR RNA, to the Rev response ele-
ment (RRE) RNA, to the virus-encoded (v)siRNA, or to
other dsRNA parts of the entering virus to form ribonucle-
oprotein complexes. These complex formations would
induce cleavage of dsRNA that would be beneficial for the
virus. An argument against this hypothesis is the activity
of vsiRNA, which is able to cleave the HIV envelope
mRNA and inhibit virus replication when Tat is mutated
[10]. In favor of this hypothesis is the positive activity of
TRBP on HIV expression and replication, the ability of
TRBP to bind TAR and RRE RNA, and the presence of short
transcripts corresponding to the size of TAR RNA during
viral infection. Although these transcripts likely stem from
an ineffective transcription [28], it cannot be excluded
that some are in fact generated by Dicer cleavage after
TRBP binding to the 5' or the 3' TAR structure of the
incoming virus. A large amount of TAR RNA in the cell
inhibits PKR [29], and this may also be the case for other
HIV small dsRNAs. This RNA-mediated inhibition would
relieve the IFN innate immunity and favor virus replica-
tion. Alternatively, TRBP in RISC could favor the cleavage
of cellular miRNAs that would favor HIV replication and
the virus would have evolved in cells producing these
RNAs. More studies on the relationship between the pres-
ence of short TAR RNAs and vsiRNAs, cellular miRNAs,
the RNAi function and PKR activity during the viral repli-
cation cycle will be needed to evaluate this hypothesis
(Fig. 2A).
2) Does HIV divert TRBP from Dicer to avoid cellular
restriction by RNAi? If RNAi is a natural mechanism to
restrict HIV replication, HIV must have developed mecha-
nisms to guarantee effective replication. One mechanism
is provided by Tat acting as an RNAi suppressor, but it
may not be the only pathway. HIV may recruit TRBP and
use it for its own benefit to avoid cleavage of its own RNA.
TRBP on TAR and RRE RNAs is utilized by the virus to
improve its own translation and replication and as a con-
sequence becomes unavailable to bind Dicer and mediate
RNAi. In this case, both TRBP and Tat would participate in
the inhibition of HIV restriction by RNAi and act in con-
cert to favor viral expression as shown earlier [18,19,23],
but by an additional mechanism. Studies on RNAi func-
tion and the levels of small RNAs during HIV replication
should help to elucidate this hypothesis (Fig. 2B).
Whether HIV co-opts the RNAi pathway for its benefit or
whether it diverts TRBP to avoid the cleavage of its RNA
remains to be elucidated, but the end result is that the
virus proceeds with replication. The final mechanism may
come from studies in human cellular models in which the
virus replicates poorly. Astrocytes represent such a model,
but other models in which either the IFN response or the
RNAi mechanism represents major cellular responses, will
certainly emerge. TRBP, with its antagonistic properties as
an anti-PKR and a pro-Dicer factor will be a key player in
the balance between these mechanisms that will lead to
viral replication or antiviral immunity.
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